NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Shilpa Medicare FY26 Revenue Grows 18% to ₹1,549 Cr; Adj. PAT Surges 135%
Shilpa Medicare reported a strong financial performance for FY26, with consolidated revenue reaching INR 1,549 crores, an 18% YoY increase. The company's profitability saw a significant boost, with EBITDA growing 30% to INR 445 crores and Adjusted PAT surging 135% to INR 232 crores. The Formulations segment was a key growth driver, increasing 30% YoY to INR 618 crores, supported by the successful launch of NorUDCA for NAFLD. Operational efficiency improved as EBITDA margins expanded to 29% and the Net Debt to EBITDA ratio decreased to 1.4x.
முக்கிய அம்சங்கள்
FY26 Revenue grew 18% YoY to INR 1,549 crores; Q4 FY26 revenue rose 30% to INR 439 crores.Adjusted PAT for FY26 increased by 135% YoY to INR 232 crores, demonstrating strong bottom-line acceleration.EBITDA margins expanded by 300 bps to 29% for FY26, driven by a favorable product mix and operating leverage.Formulations revenue grew 30% YoY in FY26, with EU revenue crossing the INR 200 crore milestone.Net Debt to EBITDA ratio improved from 1.6x in FY25 to 1.4x in FY26, reflecting better capital efficiency.
👀 கவனிக்க வேண்டியவை
Investors should note the strong turnaround in profitability and the scaling of high-margin formulations and biologics segments. The stock remains a positive watch given the upcoming transdermal patch launches in the EU and US.
Shilpa Medicare Recommends ₹0.60 Dividend and 28% Stake Acquisition in Neo Green Power
Shilpa Medicare's board has recommended a final dividend of ₹0.60 per share (60% of face value) for the financial year 2025-26. In a strategic move, the company's subsidiaries will also acquire a 28% equity stake in Neo Green Power Project Private Limited for ₹4.44 crore to meet captive renewable energy requirements. Additionally, the company has approved its audited FY26 financial results and proposed shifting its registered office from Karnataka to Maharashtra. These developments indicate a focus on shareholder returns and operational cost optimization through green energy.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.60 (60%) per equity share of face value ₹1 for FY 2025-26.Subsidiaries to acquire a 28% stake in Neo Green Power Project Private Limited for ₹4.44 crore.The acquisition is intended to secure renewable energy for captive power consumption in subsidiaries.Approved audited standalone and consolidated financial statements for FY ended March 31, 2026.Proposed shifting of the registered office from Raichur, Karnataka to the State of Maharashtra.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming AGM for dividend approval and the impact of the renewable energy investment on long-term operating margins. The shift to Maharashtra suggests a strategic relocation to a major industrial hub which may offer better administrative synergies.
Shilpa Medicare Appoints Dr. Vellaian Karuppiah as COO-Formulations; 33+ Years Experience
Shilpa Medicare has appointed Dr. Vellaian Karuppiah as the Chief Operating Officer (COO) for its Formulations division, effective April 23, 2026. Dr. Karuppiah is a pharmaceutical veteran with over 33 years of experience, having held senior leadership roles at major companies including Gland Pharma, Dr. Reddy’s Laboratories, and Strides Group. His deep expertise in R&D, manufacturing operations, and regulatory affairs is expected to drive operational excellence in the company's formulations business. This strategic hire aims to strengthen the company's growth trajectory and enhance global competitiveness.
முக்கிய அம்சங்கள்
Dr. Vellaian Karuppiah appointed as COO - Formulations effective April 23, 2026Brings over 33 years of extensive experience across the pharmaceutical value chainPrevious leadership roles at Gland Pharma, Strides Group, Dr. Reddy’s, and Teva (Actavis)Holds a Doctorate in Pharmacy and Executive Management qualifications from Tier-1 institutionsMandate includes strengthening manufacturing efficiency, quality systems, and R&D integration
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as the company brings in high-caliber talent from top-tier pharma firms to lead its formulations business. Monitor for improvements in operational margins and execution in the formulations segment over the coming quarters.
Shilpa Medicare Receives NCLT Approval for Merger with Shilpa Therapeutics
The National Company Law Tribunal (NCLT), Bengaluru Bench, has sanctioned the Scheme of Amalgamation between Shilpa Therapeutics Private Limited and its parent company, Shilpa Medicare Limited. As the transferor is a wholly-owned subsidiary, no new shares will be issued, and the existing share capital of the subsidiary will stand cancelled. The merger, with an appointed date of April 1, 2023, aims to streamline corporate structure and integrate operations. The company is now in the process of filing the certified order with the Registrar of Companies to make the merger effective.
முக்கிய அம்சங்கள்
NCLT Bengaluru Bench approved the merger of Shilpa Therapeutics (subsidiary) into Shilpa Medicare (parent) on February 27, 2026.No new shares will be issued as the transferor is a 100% subsidiary of the transferee company.The appointed date for the amalgamation is fixed as April 1, 2023.Statutory dues of ₹61.17 lakhs for the subsidiary and ₹3.59 crores for the parent were noted as of FY24 for settlement.The authorized share capital of both entities will be clubbed, and all employees will be absorbed into Shilpa Medicare.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward corporate simplification and operational synergy. Since no new shares are being issued, there is no equity dilution for existing shareholders.
Shilpa Medicare Subsidiary Partners with SteinCares to Launch Biosimilar in Latin America
Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America. SteinCares will hold exclusive rights to register and distribute the product across 30 countries in the region, while Shilpa will handle development and long-term manufacturing from its Dharwad facility. This agreement marks Shilpa Biologicals' first entry into the Latin American market, a significant step in its global biosimilar expansion. The partnership leverages SteinCares' 45 years of regional expertise to provide cost-effective specialty treatments.
முக்கிய அம்சங்கள்
Exclusive licensing agreement with SteinCares for biosimilar distribution in 30 Latin American countries.Shilpa Biologicals to provide long-term commercial manufacturing from its Dharwad, India facility.Marks the first product from this strategic partnership and Shilpa's entry into the Latin American market.SteinCares brings over 45 years of experience in specialty healthcare and biosimilars in the region.Focuses on high-value therapeutic areas including immunology, oncology, and ophthalmics.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards diversifying revenue streams and entering high-growth international markets. Monitor for future regulatory approvals and product launch timelines in specific Latin American countries to gauge revenue impact.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Shilpa Medicare Secures Strategic CDMO Partnership with NXI Therapeutics AG
Shilpa Medicare has entered into a strategic partnership with Swiss biotech firm NXI Therapeutics AG for the development and commercial manufacturing of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its growing presence in the global CDMO market. The agreement covers the entire product lifecycle, including CMC development, clinical supply, and long-term commercial manufacturing. While financial terms remain confidential, the deal includes milestone-linked expansion potential and strengthens Shilpa's high-value innovation pipeline.
முக்கிய அம்சங்கள்
Strategic partnership with NXI Therapeutics AG for development and commercial manufacturing of a novel NCE.Third significant international mandate secured by Shilpa Medicare in recent months.Scope includes CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing.Focuses on the high-growth autoimmune and immune-modulation therapeutic segment.Agreement includes milestone-linked expansion potential for future revenue visibility.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development in Shilpa Medicare's transition toward becoming a high-value CDMO partner for global biotech firms. Monitor the execution of these international mandates as they are key drivers for long-term revenue growth and margin improvement.
Shilpa Medicare Signs Strategic NCE Development Agreement with Swiss-based NXI Therapeutics
Shilpa Medicare has entered into a binding agreement with Switzerland's NXI Therapeutics AG for the development and supply of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its transition into a high-value CDMO partner. The collaboration covers the full product lifecycle, including CMC development, clinical studies, and long-term commercial GMP manufacturing. While specific financial terms are confidential, the deal includes milestone-linked expansion potential and enhances long-term revenue visibility.
முக்கிய அம்சங்கள்
Third significant international development and manufacturing contract secured in recent months.Partnership covers the entire lifecycle from early development to long-term commercial GMP manufacturing.Targets the high-growth autoimmune and alloimmune therapeutic segment globally.Agreement includes milestone-linked expansion potential and strengthens the company's CDMO platform.Collaboration with Swiss-based NXI Therapeutics leverages Shilpa's integrated R&D and manufacturing infrastructure.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of this NCE through clinical stages as it validates Shilpa's CDMO capabilities and provides long-term growth visibility. The stock remains a positive watch for those looking at the evolving Indian biotech and specialty manufacturing space.
Shilpa Medicare Q3 FY26: Highest Ever Revenue of ₹411 Cr and 41% EBITDA Growth
Shilpa Medicare reported its highest-ever quarterly performance with revenue reaching ₹411 crores, a 28% YoY increase, and EBITDA growing 41% to ₹115 crores. The company's adjusted PAT for the first nine months of FY26 at ₹146 crores has already nearly doubled the full-year PAT of FY25. Growth is primarily driven by a 50% surge in the formulations business and strong traction in the European market. Management is shifting focus from heavy R&D investment to execution, with significant product launches like Rotigotine and NorUDCA expected to drive future ROCE.
முக்கிய அம்சங்கள்
Reported highest-ever quarterly revenue of ₹411 crores, up 28% YoY, and EBITDA of ₹115 crores, up 41% YoY.Formulation business revenue grew 50% YoY to ₹177 crores, with European formulation sales increasing over 100%.Adjusted ROCE (excluding long-term R&D) improved significantly to over 17% in 9M FY26 from 3.5% in FY23.Received EMA approval for Rotigotine transdermal patch with launch planned for Q1 FY27 and ADC facility commissioning in Q4 FY26.9M FY26 PAT of ₹146 crores nearly doubles the total PAT recorded in the entire previous fiscal year (FY25).
👀 கவனிக்க வேண்டியவை
Investors should view the strong operating leverage and improving ROCE as a sign of successful transition from an investment phase to a commercialization phase. Monitor the upcoming launch of Rotigotine in Europe and the progress of the high-value Biologics and ADC pipeline for long-term value.
Shilpa Medicare Q3 FY26 Results: Consolidated Net Profit Jumps 40% YoY to ₹44.58 Crore
Shilpa Medicare reported a robust performance for Q3 FY26, with consolidated revenue growing 28.3% YoY to ₹409.73 crore. Net profit for the quarter rose significantly by 40.3% YoY to ₹44.58 crore, driven by strong operational execution despite a marginal 1.2% growth on a sequential basis. A major strategic milestone was achieved with the filing of the Rotigotine Transdermal System, the company's first transdermal patch ANDA, with the USFDA. The company also reconstituted its Audit Committee, inducting Mr. Ashraf Allam as an independent director.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations increased to ₹409.73 crore, up 28.3% from ₹319.30 crore in Q3 FY25.Net Profit attributable to owners grew 40.3% YoY to ₹44.58 crore compared to ₹31.78 crore in the previous year.Nine-month (9M FY26) consolidated profit reached ₹135.53 crore, more than doubling from ₹63.79 crore in 9M FY25.Filed the first Transdermal Patch ANDA (Rotigotine) with the USFDA, targeting the complex generics market.Consolidated EPS for the quarter stood at ₹2.36, up from ₹1.63 in the corresponding quarter of the previous year.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant YoY profit growth and the strategic entry into the high-entry-barrier transdermal patch segment. The stock remains a positive long-term play as the company transitions toward more complex generic formulations.
Shilpa Medicare Q3 FY26: Adj. PAT Surges 72% YoY to ₹55 Cr; Highest Ever Quarterly Revenue
Shilpa Medicare reported its strongest-ever quarterly performance in Q3 FY26, with revenue growing 28% YoY to ₹411 crore and adjusted PAT jumping 72% to ₹55 crore. The growth was driven by a 50% surge in the Formulations segment and robust traction in Biologics, while EBITDA margins expanded by 200 bps to 28%. For the 9M FY26 period, the company has already surpassed its full-year FY25 PAT, reaching ₹146 crore. Management highlighted significant progress in high-value product launches, including NorUDCA for NAFLD in India and EU approval for the Rotigotine patch.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 28% YoY to ₹411 crore, marking the highest quarterly revenue in the company's history.Adjusted PAT for the quarter rose 72% YoY to ₹55 crore, while 9M FY26 PAT doubled compared to the full-year FY25 PAT.EBITDA increased 40% YoY to ₹115 crore with margins improving to 28% from 26% in the previous year.Formulations segment saw 50% YoY growth, specifically driven by a 107% revenue increase in the EU market.Net Debt to EBITDA improved to 1.4x from 1.6x in FY25, alongside an improved Adjusted ROCE of 17.1%.
👀 கவனிக்க வேண்டியவை
Investors should note the significant margin expansion and the successful commercialization of the R&D pipeline, particularly in complex generics and biologics. The stock remains attractive for long-term investors as the company transitions toward higher-margin specialty products and improves its capital efficiency.
Shilpa Medicare Subsidiary Gets US FDA Orphan Drug Designation for Rare Blood Cancer Biologic
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has achieved a major milestone with the US FDA granting Orphan Drug Designation (ODD) to its monoclonal antibody for treating rare blood cancers. The designation covers Essential Thrombocythemia (ET) and Polycythemia Vera (PV), conditions with high unmet medical needs. This regulatory status provides the company with development support, tax credits, and potential market exclusivity upon final approval. The company is now progressing toward IND-enabling studies to initiate first-in-human clinical trials.
முக்கிய அம்சங்கள்
US FDA grants Orphan Drug Designation for a flagship biologic targeting ET and PV rare blood cancers.Designation provides commercial incentives including tax credits and potential 7-year market exclusivity.The biologic targets immune-evasion pathways, offering a differentiated profile from existing JAK inhibitors.Shilpa Biologicals and mAbTree Biologics to advance the program to IND-enabling studies and human trials.Milestone validates Shilpa Medicare's R&D capabilities in the high-value biologics and critical care space.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term development that strengthens the company's specialized R&D pipeline. Monitor future updates regarding IND filings and clinical trial progress as these will be the next major valuation catalysts.
Shilpa Medicare Receives Delhi High Court Injunction Over Ruxolitinib Patent Infringement
Shilpa Medicare and its subsidiaries have received an ex-parte ad-interim injunction from the Delhi High Court regarding the drug Ruxolitinib. The order restrains the company from manufacturing, exporting, or selling the product due to alleged infringement of Patent No. IN269841. The company clarified that the product was used solely for research purposes and claims there is no immediate financial impact on current operations. While a Local Commissioner inspected the premises and records, the company reports that business continues as usual.
முக்கிய அம்சங்கள்
Delhi High Court issued an injunction against Shilpa Medicare and two subsidiaries regarding Ruxolitinib API.The order restrains manufacturing, stockpiling, and exporting of products infringing Patent No. IN269841.Company states the drug was utilized for research purposes only with no current financial impact.Local Commissioner inspected office premises and stock registers on December 29, 2025.Shilpa Medicare is evaluating legal options including filing responses or appeals against the order.
👀 கவனிக்க வேண்டியவை
Investors should monitor the legal proceedings for any potential penalties or restrictions on future product launches. While the immediate financial impact is nil, patent litigation can affect the company's R&D pipeline and legal expenses.
Shilpa Medicare Gets European Nod for Rotigotine Patch; Targets $222M Market
Shilpa Medicare has received initial European authorization for its Rotigotine transdermal patch, a generic version of Neupro used for Parkinson’s and Restless Legs Syndrome. The company is targeting a total addressable European market estimated at approximately USD 222 million. A strategic commercialization partner has already been onboarded, with a targeted launch set for FY27. This marks the company's first transdermal patch approval in Europe and the first from its specialized Unit VI facility in Bengaluru.
முக்கிய அம்சங்கள்
Received initial European authorization for Rotigotine patches in strengths ranging from 1mg to 8mg.Targets a total addressable European market for Rotigotine estimated at USD 222 million.First transdermal patch dosage form for Shilpa Medicare to receive marketing authorization in Europe.Strategic commercialization partner already onboarded with a targeted launch in FY27.Approval received for the Unit VI manufacturing facility located at Dobbaspet, Bengaluru.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from initial to final marketing authorization and the subsequent launch in FY27, which strengthens the company's complex generics portfolio.
Shilpa Medicare Q2 Consolidated Net Profit Surges 145% YoY to ₹44.07 Crore
Shilpa Medicare reported a strong performance for Q2 FY25, with consolidated revenue growing to ₹369.97 crore compared to ₹343.80 crore in the same quarter last year. The net profit saw a massive jump of approximately 145.7% YoY, reaching ₹44.07 crore, significantly aided by a reduction in finance costs which dropped from ₹25.55 crore to ₹15.67 crore. On a half-yearly basis, the company's profit nearly tripled to ₹90.95 crore from ₹32.00 crore in the previous year. The results indicate strong operational turnaround and improved balance sheet management.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations grew 7.6% YoY to ₹369.97 crore in Q2 FY25.Consolidated Net Profit surged 145.7% YoY to ₹44.07 crore from ₹17.94 crore in the year-ago period.Finance costs were significantly reduced by 38.7% YoY to ₹15.67 crore in Q2 FY25.H1 FY25 Consolidated Net Profit reached ₹90.95 crore, a 184% increase compared to H1 FY24.Basic EPS for the quarter improved to ₹2.25 from ₹0.92 in Q2 FY24.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the sharp reduction in interest expenses as a sign of improving financial health. The stock may see positive momentum given the substantial bottom-line growth and operational efficiency.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
